Dachaigh › Myeloma iomaill › Utah › Salt Lake City
Sgrùdaidhean clionaigeach Myeloma iomaill ann an Salt Lake City, UT
Tha 21 sgrùdaidhean airson Myeloma iomaill a’ lorg phàirtichean aig làraichean ann agus timcheall air Salt Lake City (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A’ fastadhÌre 3
- Research Site, Salt Lake City
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
A’ fastadhÌre 1/2
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 3
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 3
- Utah Cancer Specialists, Salt Lake City
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
A’ fastadhÌre 3
- LDS Hospital, Salt Lake City
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A’ fastadhÌre 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
A’ fastadhÌre 2
- Intermountain Healthcare, Salt Lake City
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
A’ fastadhÌre 3
- Huntsman Cancer Institute, Salt Lake City
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 2
- LDS Hospital, Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A’ fastadhÌre 1/2
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
A’ fastadhÌre 2
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
A’ fastadhÌre 2
- Huntsman Cancer Institute, Salt Lake City
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
A’ fastadhÌre 1/2
- Research Site, Salt Lake City
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A’ fastadhÌre 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
A’ fastadhÌre 1/2
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
A’ fastadhÌre 2
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A’ fastadhÌre 1
- Huntsman Cancer Center Institute University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
A’ fastadhÌre 1
- University of Utah, Salt Lake City
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A’ fastadhÌre 1/2
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
A’ fastadhSgrùdadh amharc
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
A’ fastadhÌre 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Sgrùdaidhean Myeloma iomaill ann am bailtean eile
- New York City, NY60 sgrùdaidhean
- Boston, MA42 sgrùdaidhean
- Atlanta, GA42 sgrùdaidhean
- Houston, TX38 sgrùdaidhean
- Durham, NC37 sgrùdaidhean
- Nashville, TN32 sgrùdaidhean
- Denver, CO27 sgrùdaidhean
- Rochester, MN24 sgrùdaidhean
- St. Louis, MO24 sgrùdaidhean
- Columbus, OH24 sgrùdaidhean
- Baldwin Park, CA23 sgrùdaidhean
- Edison, NJ22 sgrùdaidhean
Sgrùdaidhean eile ann an Salt Lake City
- Aillse Sgamhain Neo-chealla-beag31 sgrùdaidhean
- Aillse (gach seòrsa)27 sgrùdaidhean
- Aillse a' bhroilleach27 sgrùdaidhean
- Aillse colorectal22 sgrùdaidhean
- Ailseachadh nan Sgamhan21 sgrùdaidhean
- Melanoma21 sgrùdaidhean
- Ailse metastatach20 sgrùdaidhean
- Cancer Ovarian19 sgrùdaidhean
- Obesity18 sgrùdaidhean
- Leukemia myeloid geur17 sgrùdaidhean
- Fàilligeadh a' Chridhe17 sgrùdaidhean
- Aillse Prostata15 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.